Welcome to our dedicated page for Century Therapeutics SEC filings (Ticker: IPSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Century Therapeutics’ SEC filings rarely read like simple financial statements. Each 10-K weaves stem-cell science, Allo-Evasion™ gene edits and cash-burn projections into 200+ pages, leaving investors hunting for clear answers. Stock Titan fixes that problem.
Our AI-powered reader turns every Century Therapeutics SEC filing into plain-English insights. Want the latest “Century Therapeutics quarterly earnings report 10-Q filing” summarized before the market opens? We tag key figures—R&D spend, clinical trial milestones, liquidity runway—and deliver context in seconds. Need “Century Therapeutics insider trading Form 4 transactions” alerts? Real-time feeds flag executive stock moves, so you can follow “Century Therapeutics executive stock transactions Form 4” without refreshing EDGAR.
You’ll find every document, from the “Century Therapeutics annual report 10-K simplified” to “Century Therapeutics 8-K material events explained,” all indexed the moment they hit the SEC. Our platform connects forms to what matters for this particular biotech:
- 10-K: Pipeline status, manufacturing capacity and Allo-Evasion™ IP disclosures
- 10-Q: Quarterly cash burn and trial read-outs
- 8-K: Partnership deals, FDA designations and clinical setbacks
- DEF 14A proxy: “Century Therapeutics proxy statement executive compensation” showing R&D incentive structures
- Form 4: “Century Therapeutics Form 4 insider transactions real-time” for sentiment signals before data drops
Stop scrolling through dense PDFs. Stock Titan’s expert analysis, natural-language summaries and adjustable redline comparisons let you understand “Century Therapeutics SEC filings explained simply” and act on them faster.
Century Therapeutics, Inc. received a deficiency letter from Nasdaq after its closing bid price fell below the $1.00 minimum over the last 30 consecutive business days, triggering a 180-day compliance period that ran to August 26, 2025. Nasdaq determined the company otherwise met market value and initial listing requirements for The Nasdaq Capital Market and accepted the company's plan to cure the deficiency, including a possible reverse stock split. On August 27, 2025 Nasdaq approved Century's transfer from The Nasdaq Global Select Market to The Nasdaq Capital Market and the company's common stock continues to trade under the symbol IPSC. The filing notes the transfer became effective at the opening of business on August 27, 2025, although one date in the text appears truncated.
Century Therapeutics (IPSC) filing notifies a proposed sale under Rule 144 of 30,745 common shares with an aggregate market value of $17,521.58. The shares represent restricted stock that vested and were acquired on 08/15/2025 and the filer intends to sell on or about 08/18/2025 through Fidelity Brokerage Services on NASDAQ. The filing shows 86,389,098 shares outstanding for the issuer. It also discloses a prior sale by the same person of 475 shares on 06/09/2025 for $295.50. The acquisition payment is listed as compensation. The signer certifies no undisclosed material adverse information.
Brent Pfeiffenberger, President and CEO and a director of Century Therapeutics, Inc. (IPSC), received a grant of 1,587,614 restricted stock units (RSUs) on 08/14/2025. Each RSU converts into one share of common stock and will settle in shares on vesting. The RSUs vest 50% on August 14, 2027 and the remaining 50% on August 14, 2028, each tranche conditioned on continued service through the vesting date. The reported transaction shows an acquisition at a reported price of $0 and indicates 3,269,397 shares beneficially owned by the reporting person after the transaction. The Form 4 was filed for this single reporting person and signed by an attorney-in-fact on 08/18/2025.
Century Therapeutics (IPSC) reported operational updates reflecting continued development of its iPSC-derived cell therapy pipeline and recent acquisition activity. The company disclosed 86,322,071 shares outstanding at June 30, 2025 versus 85,836,429 at December 31, 2024. Century completed the acquisition of Clade, issuing 3,741,646 common shares at close and recording holdback shares of up to 793,687 subject to indemnification adjustments. Contingent consideration at closing included a fair-value amount of $2,600 plus a potential Clade milestone valued at $8,883, and a possible milestone payment of $10,000 payable in cash, shares, or combination.
The filing outlines program progress and capabilities including lead candidate CNTY-101, preclinical programs from Clade, and additional CAR-iT candidates (CNTY-308, CNTY-341) using the company’s Allo-Evasion™ and iPSC platforms. The company reported prior ATM sales of 4,084,502 shares for net proceeds of $17,829 in the six months ended June 30, 2024 and no ATM sales in the six months ended June 30, 2025. Quarter-over-quarter operating expense shifts include G&A of $7.8M versus $8.3M in the prior-year quarter and mixed R&D and facility cost changes driven by staff reductions, consolidation of lab operations, and completion of a manufacturing campaign under the FCDI collaboration.
FAQ
What is the current stock price of Century Therapeutics (IPSC)?
What is the market cap of Century Therapeutics (IPSC)?
